Question 1 · Hard
A laboratory that follows EUCAST tests a Pseudomonas aeruginosa blood isolate from a ventilated patient against piperacillin-tazobactam with a gradient strip. The inhibition ellipse meets the strip at 12 mg/L. Quality control with P. aeruginosa ATCC 27853 is within range. The laboratory's current EUCAST breakpoint table lists, for P. aeruginosa and piperacillin-tazobactam: S ≤0.001 mg/L, R >16 mg/L, with a note that the breakpoints apply to high-dose therapy. How should the result be reported?
- AMIC 16 mg/L: resistant
- BMIC 16 mg/L: intermediate, so avoid the drug
- CMIC 12 mg/L: susceptible, standard dosing
- DMIC 16 mg/L: susceptible, increased exposure
Show answerHide answer
Answer: D · MIC 16 mg/L: susceptible, increased exposure
A gradient strip reading that falls between twofold dilutions is rounded up before interpretation, so 12 mg/L is reported as 16 mg/L. EUCAST sets the susceptible breakpoint for P. aeruginosa at an off-scale 0.001 mg/L, so wild-type isolates are never categorised 'S' but 'I'. An MIC of 16 mg/L is not above the resistant breakpoint of >16 mg/L, so the category is I: susceptible, increased exposure. This means the drug is expected to work if given at the high dose or by extended infusion in the EUCAST dosing table, and the report should make that clear. CLSI uses different breakpoints, so a laboratory must apply one system consistently.
- A: An MIC of 16 is not above the resistant breakpoint of >16 mg/L.
- B: EUCAST 'I' means susceptible at increased exposure, not a drug to avoid.
- C: Gradient readings are rounded up, and under these breakpoints no MIC above 0.001 mg/L is S.